Identification | Back Directory | [Name]
INF39 | [CAS]
866028-26-4 | [Synonyms]
INF39 CS-2508 INF39 >=98% (HPLC) INF-39;INF 39;INF39 Ethyl 2-(2-chlorobenzyl)acrylate Benzenepropanoic acid, 2-chloro-α-methylene-, ethyl ester | [Molecular Formula]
C12H13ClO2 | [MDL Number]
MFCD27930542 | [MOL File]
866028-26-4.mol | [Molecular Weight]
224.68 |
Chemical Properties | Back Directory | [Boiling point ]
309.3±30.0 °C(Predicted) | [density ]
1.131±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMSO:66.0(Max Conc. mg/mL);293.75(Max Conc. mM) Ethanol:30.0(Max Conc. mg/mL);133.52(Max Conc. mM) | [form ]
oil | [color ]
colorless to light brown |
Hazard Information | Back Directory | [Uses]
INF 39 is a NLRP3 inflammasome inhibitor. Used in the treatment of inflammatory bowel disease. | [Biochem/physiol Actions]
INF39 is an orally active acrylate derivative and a non-cytotoxic INF4E analog (no toxicity at 100 μM in THP-1 cultures vs. TC50 = 65 μM with INF4E) that acts as an irreversible inhibitor against NLRP3 (NACHT, LRR and PYD domains-containing protein 3) ATPase activity (52% inhibition in 15 min by 100 μM INF39; 105 ng human NLP3 & 250 μM ATP) essential for the NLRP3 inflammasome assembly and activation. INF39 effectively decreases 5 mM (30 min) ATP-induced interleukin-1β (IL-1β) release and pyroptosis of murine bone marrow-derived macrophages in cultures (by 55-58% and 43-65%, respectively, with 1-hr 10 μM INF39 pretreatment of LPS-primed BMDM) and alleviates gut-associated inflammation in a rat model of 2,4-dinitrobenzenesulfonic acid (DNBS)-induced colitis in vivo (12.5-50 mg/kg/day in 0.2 mL olive oil p.o.). | [storage]
Store at -20°C |
|
Company Name: |
Sigma-Aldrich
|
Tel: |
021-61415566 800-8193336 |
Website: |
https://www.sigmaaldrich.cn |
|